Ziopharm Message Board - Msg: 30963832

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ziopharm

ZIOP 0.866

-0.9%

Jan 26 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: PLegee	2/1/2017 9:41:29 AM
	Read Replies (1) of 14

Of the two non-clinical obstacles in Ziop's price performance path (sector/pricing, cash raise), Trump's meeting with the biopharm CEO's yesterday seemed to go much better than originally anticipated. Analyst Michael Yee (sp) from RBC thought that the govt and industry goals aligned for the most part; expediting FDA trials (if safety is not an issue) would ultimately reduce costs. Trump acknowledged the burden and cost disproportionately placed on US bio firms. I'm not clear how much cash repatriation (also briefly touched upon) will ultimately help the biotech industry at large, but many claim it should be a tailwind for all bio pps. Not a ZIOP specific issue however. Looks like near term pps could be going higher for ZIOP, the 50 dma is just a few cents above current price, that will bear watching. Of course, the big elephant in the room remains operational cash; no recent news on that front. A big trial success would take prices higher allowing for a more reasonable secondary offering if that is the path management chooses to go. I'm sure they have other options as well.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next